Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-4008 in FGFR2-altered Cholangiocarcinoma and Solid Tumors
NCT04526106Phase 2Completed
- Sponsor
- Elevar Therapeutics
- Start
- Sep 2020
- Primary completion
- Sep 2025
- Countries
- 13
01
Overview
A Phase 2 trial of lirafugratinib in cholangiocarcinoma (CCA), intrahepatic cholangiocarcinoma (ICC), solid tumor, sponsored by Elevar Therapeutics. Started Sep 2020; status: completed.
02
Drugs
lirafugratinib
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)solid tumor
Beyond the preview
Go deeper on NCT04526106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526106.